Evidence & regulatory context
- Mechanism
- Genetic knockout of the polyamine catabolic enzyme SSAT plus pharmacological polyamine oxidase inhibition, reducing hydrogen peroxide generation from polyamine back-conversion. Genetic tool with no ChEMBL drug entity; ClinicalTrials.gov returned no polyamine oxidase inhibitor trials.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- SSAT; SAT1; Polyamine oxidase inhibitor; MDL 72527
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinHepatocyte-specific SSAT knockout (Hep-SSAT-Cko) and wild-type mice
Model: Carbon tetrachloride (CCl4) induced acute toxic liver injury
Early liver injury after CCl4 was significantly attenuated in hepatocyte-specific SSAT knockout mice, with lower serum alanine aminotransferase, less hepatic lipid peroxidation and less severe histological damage, and polyamine oxidase inhibition was also protective. However, the onset of hepatocyt…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
